Dopaminergic Drugs in Cardiovascular Emergencies

  • M. F. Lokhandwala
  • B. S. Jandhyala
  • S. M. Jacinto
Conference paper
Part of the Yearbook of Intensive Care and Emergency Medicine book series (YEARBOOK, volume 1995)


Drugs acting at dopamine (DA) receptors provide an important therapeutic approach in the treatment of various cardiovascular emergencies [1–3]. Peripheral dopamine receptors are classified into two distinct subtypes, namely DA-1 and DA-2 [1–3]. Whereas DA, in addition to stimulating both DA-1 and DA-2 receptors, also activates α- and β-adrenoceptors, there are compounds available which preferentially activate either DA-1 and/or DA-2 receptors and do not stimulate a- and β-adrenoceptors. The major cardiovascular consequence following stimulation of DA receptors include decreases in cardiac afterload or peripheral vascular resistance, increases in cardiac index, mesenteric and renal blood flows as well as natriuresis and diuresis. The dopaminergic drugs currently available for the treatment of cardiovascular emergencies include dopamine, fenoldopam and dopexamine.


Cardiac Index Renal Blood Flow Hemorrhagic Shock Mean Blood Pressure Dopaminergic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lokhandwala MF, Hegde SS (1991) Cardiovascular pharmacology of adrenergic and dopaminergic receptors: Therapeutic significance in congestive heart failure. Am J Med 90 (Suppl 5B): 5–9Google Scholar
  2. 2.
    Chen CJ, Lokhandwala MF (1992) Dopamine receptor agonists in cardiovascular pharmacotherapy. Ind J Pharmacol 24: 72–81Google Scholar
  3. 3.
    Lokhandwala MF, Chen CJ (1993) Peripheral dopamine receptors. In: Niznik HB (ed) Dopamine receptor function and pharmacology. Marcel Dekker, New York, pp 89–92Google Scholar
  4. 4.
    Hegde SS, Lokhandwala MF (1988) Involvement of cyclic-AMP in the hypotensive response to fenoldopam but not to quinpirole in the anesthetized rat. J Auton Pharmacol 8: 63–88PubMedCrossRefGoogle Scholar
  5. 5.
    Felder CC, McKelvey AM, Gitler MS, Eisner GM, Jose PA (1989) Dopamine receptor subtypes in renal brushborder and basolateral membranes. Kidney Int 36: 183–193PubMedCrossRefGoogle Scholar
  6. 6.
    Lokhandwala MF, Amenta F (1991) Anatomical distribution and function of dopamine receptors in the kidney. FASEB J 5: 3023–3030PubMedGoogle Scholar
  7. 7.
    Bertorello AM, Katz AI (1993) Short term regulation of renal Na-K-ATPase activity: Physiological relevance and cellular mechanisms. Am J Physiol 265: F743–F755PubMedGoogle Scholar
  8. 8.
    Vyas SJ, Jadhav AL, Eichberg J, Lokhandwala MF (1992) Dopamine receptor-mediated activation of phospholipase-C is associated with natruresis during high sodium intake. Am J Physiol 262: F494–F498PubMedGoogle Scholar
  9. 9.
    van Veldhuisen DK, Gribes ARJ, deGraeff PA, Lie KI (1992) Effects of dopaminergic agents on cardiac and renal function in normal man and in patients with congestive heart failure. Int J Cardiol 37: 293–300PubMedCrossRefGoogle Scholar
  10. 10.
    Maskin CS, Ocken S, Chadwick B, LeJemtel TH (1985) Comparative systemic and renal effects of dopamine and angiotensin-converting enzyme inhibition with enalaprilat in patients with heart failure. Circulation 72: 846–852PubMedCrossRefGoogle Scholar
  11. 11.
    Szerlip HM (1991) Renal-dose dopamine: Fact and fiction. Ann Intern Med 115: 153–154PubMedGoogle Scholar
  12. 12.
    Linder A (1983) Synergism of dopamine and furosemide in diuretic-resistant oliguric acute renal failure. Nephron 37: 39–42Google Scholar
  13. 13.
    Lokhandwala MF (1991) Effects of dopamine receptor agonists on cardiovascular and renal function. In: Vincent JL (ed) Update in intensive care and emergency medicine, Vol 14. Springer-Verlag, Berlin, pp 74–80Google Scholar
  14. 14.
    Nichols AJ, Koster PF, Brooks DP, Ruffolo RR Jr (1992) Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog. J Pharmacol Exp Therapy 260: 269–274Google Scholar
  15. 15.
    Wang YX, Gellai M, Brooks DP (1992) Dopamine DA1 receptor agonist, fenoldopam, reverses glycine-induced hyperfiltration in rats. Am J Physiol 262: F1055–F1060PubMedGoogle Scholar
  16. 16.
    Brodde OE (1991) Beta 1- and beta 2-adrenoceptors in the human heart: Properties, function, and alterations in chronic heart failure. Pharmacol Rev 43: 203–242PubMedGoogle Scholar
  17. 17.
    Vincent JL (ed) (1991) Towards improving vital organ function: Assessing the role of dopexamine hydrochloride in intensive care medicine. Clin Intensive Care 2 (Suppl): 5–54Google Scholar
  18. 18.
    Boyd O, Bennett ED (1992) Effects of dopexamine hydrochloride in a porcine sepsis model and in high-risk peri-operative surgical patients. Clin Intensive Care 3 (Suppl): 32–36Google Scholar
  19. 19.
    Gray PA, Bodeham AR, Park GR (1991) A comparison of dopexamine and dopamine to prevent renal impairment in patients undergoing orthotopic liver transplantation. Anaesthesia 46: 638–641PubMedCrossRefGoogle Scholar
  20. 20.
    Atallah MM, Saied MMA, El-Diasty TA, Gray PA, Park GR (1992) Renal effects of dopexamine hydrochloride in patients with chronic renal dysfunction. Urol Res 20: 419–424PubMedCrossRefGoogle Scholar
  21. 21.
    Chintala MS, Lokhandwala MF, Jandhyala BS (1990) Protective effects of dopexamine hydrochloride in renal failure after acute hemorrhage in anesthetized dogs. J Auton Pharmacol 10 (Suppl): S95–S102PubMedCrossRefGoogle Scholar
  22. 22.
    Chintala MS, Moore RJ, Lokhandwala MF, Jandhyala BS (1993) Evaluation of the effects of dopexamine, a novel DA-1 receptor and β2-adrenoceptor agonist, on cardiac function and splanchnic circulation in a canine model of hemorrhagic shock. Naunyn-Schmiedeberg’s Arch Pharmacol 347: 396–400CrossRefGoogle Scholar
  23. 23.
    Jacinto MS, Lokhandwala MF, Jandhyala BS (1994) Studies on pharmacological interventions to prevent free radical (OFC)-mediated toxicity: Effects of Dopexamine, a DA1 receptor and β2-adrenoceptor agonist. Naunyn-Schmiedeberg’s Arch Pharmacol 350: 277–283CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • M. F. Lokhandwala
  • B. S. Jandhyala
  • S. M. Jacinto

There are no affiliations available

Personalised recommendations